Sue Hammond

AstraZeneca (United Kingdom) — United Kingdom

Medicine · Health Sciences

43h-index8.5kcitations134works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Childhood Cancer Survivors' Quality of Life(49), Acute Lymphoblastic Leukemia research(30), Cancer-related Molecular Pathways(16), Neuroblastoma Research and Treatments(13), Renal and related cancers(10)

Publications133 total

48eP Concurrent binding to PD-1 and CTLA-4 mechanistically differentiates volrustomig from the combination of monospecific antibodies ex vivo
Annals of Oncology·2025
Integrating Qualitative Insights with Large Secondary Dataset: A Protocol for a Community-Engaged Mixed-Methods Study on Adolescent Substance Use
2025Open Access
Supplementary Figure 2 from Somatic and Germline <i>TP53</i> Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors
2023Open Access
Supplementary Files from Somatic and Germline <i>TP53</i> Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors
2023Open Access
Data from Chemotherapy and Thyroid Cancer Risk: A Report from the Childhood Cancer Survivor Study
2023Open Access
Supplementary Figure 1 from Somatic and Germline <i>TP53</i> Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors
2023Open Access
Data from FANCD2 Is a Potential Therapeutic Target and Biomarker in Alveolar Rhabdomyosarcoma Harboring the PAX3–FOXO1 Fusion Gene
2023Open Access
Data from Somatic and Germline <i>TP53</i> Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors
2023Open Access
Supplementary Figure Legends from FANCD2 Is a Potential Therapeutic Target and Biomarker in Alveolar Rhabdomyosarcoma Harboring the PAX3–FOXO1 Fusion Gene
2023Open Access
Supplementary Figure 1 from FANCD2 Is a Potential Therapeutic Target and Biomarker in Alveolar Rhabdomyosarcoma Harboring the PAX3–FOXO1 Fusion Gene
2023Open Access
Supplementary Table 1 from Somatic and Germline <i>TP53</i> Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors
2023Open Access
Supplementary Legend from Somatic and Germline <i>TP53</i> Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors
2023Open Access
Supplementary Tables 1 - 4 from FANCD2 Is a Potential Therapeutic Target and Biomarker in Alveolar Rhabdomyosarcoma Harboring the PAX3–FOXO1 Fusion Gene
2023Open Access
Supplementary Legend from Somatic and Germline <i>TP53</i> Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors
2023Open Access
Supplementary Figure 2 from FANCD2 Is a Potential Therapeutic Target and Biomarker in Alveolar Rhabdomyosarcoma Harboring the PAX3–FOXO1 Fusion Gene
2023Open Access
Supplementary Figure 4 from Somatic and Germline <i>TP53</i> Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors
2023Open Access
Supplementary Figure 2 from FANCD2 Is a Potential Therapeutic Target and Biomarker in Alveolar Rhabdomyosarcoma Harboring the PAX3–FOXO1 Fusion Gene
2023Open Access
Supplementary Figure 3 from Somatic and Germline <i>TP53</i> Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors
2023Open Access
Data from Chemotherapy and Thyroid Cancer Risk: A Report from the Childhood Cancer Survivor Study
2023Open Access
Data from Somatic and Germline <i>TP53</i> Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors
2023Open Access
page 1 of 7Next →

Frequent Co-authors

Leslie L. Robison(29), Joseph P. Neglia(28), Anna T. Meadows(18), Wendy M. Leisenring(17), Ann Mertens(16), Marilyn Stovall(14), Peter D. Inskip(14), Sarah S. Donaldson(13), Marilyn Stovall(12), Susan A. Smith(12), Gregory T. Armstrong(11), John Whitton(9), Cécile M. Ronckers(8), Debra L. Friedman(7), Yutaka Yasui(7), Tara O. Henderson(7), Charles A. Sklar(6), Alice J. Sigurdson(6), Lisa Diller(6), Rita E. Weathers(6)